The global autoimmune diagnostics market size was worth USD 14.03 billion in 2020 and is forecasted to worth USD 16.74 billion by the end of 2025. This market to register a CAGR of 3.6% between 2020 to 2025.
Autoimmune disease is a disorder where the patient’s immune system attacks its body tissues, leading to body organs' damage. Nearly 80 types of autoimmune diseases are known so far.
The global autoimmune diagnostics market is forecasted to have tremendous growth during the forecast period. It is receiving a significant boost from factors such as a rise in the prevalence of autoimmune disorders like people with type 1 diabetes in newborn babies with copulation of demand for rapid diagnostics. The high incidences of autoimmune diseases and growing awareness about autoimmune diseases are further contributing to the growth of the market.
Additionally, a rise in R & D on autoimmune diseases is predicted to favor the growth rate of the market. Across the globe, many research and diagnostics industries are undertaking new initiatives with a complication with government organizations by owning a rise in the prevalence of autoimmune disorders. They will have a consequence on healthcare expenditure, as per the National Institutes of Health (NIH) data published that these disorders are in the top ranking, which leads to an increment in mortality rates among women. The factors mentioned above are the primary and significant drivers of the autoimmune diagnostics market.
Some of the restraints factors, such as the high frequency of false-positive results, and having an extended turnaround time for diagnostic test results, limit the market growth to a small extent. High expenditures, less awareness regarding various diseases, and diagnostic measures are other significant restraints. Moreover, fewer income companies and the rise of economy countries to address some issues for autoimmune diseases diagnostics market.
Impact of COVID-19 on the global autoimmune diagnostics market:
COVID-19 pandemic outbreak terrifically affected every market. After the WHO (World Health Organization) official announcement, it is observed that the COVID-19 pandemic changed the dynamic of the market, trends, and observed requirements. COVID-19 pandemic outbreak affected with the inclusion of current and future impact overall industry growth. Due to the rise in crisis, changes in requirements and trends are changing the economy's landscape. The primary wish of every market to get a vaccine for COVID-19 as soon as possible.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Test Type, Disease Type & Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Bio-Rad, Siemens Healthcare, Abbott Laboratories, Crescendo Bioscience, Roche Diagnostics SQI Diagnostics, AESKU Diagnostics, INOVA Diagnostics Inc., BioMerieux SA, Beckman Coulter Inc., Hemagen Diagnostics, Quest Diagnostics, Eli lilly and GlaxoSmithKline Plc. |
This research report on the global autoimmune diagnostics market has been segmented and sub-segmented based on the test type, disease type, and region.
Autoimmune Diagnostics Market - By Test Type:
Autoimmune Diagnostics Market - By Disease Type:
Autoimmune Diagnostics Market - By End User:
Based on the end-user, the hospital segment contributes a significant share by recording a high compound annual growth rate in the global autoimmune diagnostics market. The hospital segment is owning many advantageous factors such as increment of patients' usage and the rise of chronic diseases cases.
Autoimmune Diagnostics Market - By Region:
Geographically, the North American region is estimated to rule the global autoimmune diagnostics market during the forecast period with the highest share, followed by Europe, Asia Pacific. The Asia-pacific market is expected to account for the highest growth during the forecast period.
As anticipated, the North American region contributed to the highest revenue share above 39.2% in 2019. This North American region is owning factors such as the presence of favorable initiatives and regulations by AARDA. Moreover, the North American area is also having a high prevalence of diseases.
During the forecast period, the Asia-Pacific region is having lucrative growth-share by owning many advantageous factors such as improving healthcare infrastructure and the rapid growth of patients’ awareness levels. Moreover, the Asia-Pacific region is having a rise in an increment of revenue share. The expected revenue share of the autoimmune diagnostics market in the Asia-Pacific region has a CAGR of over 22.0% from 19.5% in 2015 to 2025.
The European region is also accounting highest share due to presence of UK country during the forecast period. The European region is having advantageous factors such as increment of economic burden with copulation with increased research and developed activities further influencing the European region's growth. Additionally, the increment of demand for better and accurate diagnosis for systematic localized diseases positively impacts the autoimmune diagnostic market.
KEY MARKET PLAYERS:
Notable participants leading the global autoimmune diagnostics market profiled in the report are Bio-Rad, Siemens Healthcare, Abbott Laboratories, Crescendo Bioscience, Roche Diagnostics SQI Diagnostics, AESKU Diagnostics, INOVA Diagnostics Inc., BioMerieux SA, Beckman Coulter Inc., Hemagen Diagnostics, Quest Diagnostics, Eli Lilly and GlaxoSmithKline Plc.
MAJOR HAPPENINGS IN THIS MARKET IN THE RECENT PAST:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Test Type
5.1.1 Autoantibody Tests
5.1.2 Antinuclear Antibody Tests
5.1.3 Complete Blood Count (CBC)
5.1.4 C - reactive protein (CRP)
5.1.5 Comprehensive Metabolic panel
5.1.6 Urinalysis
5.1.7 Erythrocyte Sedimentation Rate (ESR)
5.1.8 Others
5.2 By Disease Type
5.2.1 Localized auto immune disease diagnostics
5.2.1.1 Graves' Disease
5.2.1.2 Hashimoto's Thyroiditis
5.2.1.3 Multiple Sclerosis
5.2.1.4 Type 1 diabetes
5.2.1.5 Psoriasis
5.2.1.6 Others
5.2.2 Systemic auto immune disease diagnostics
5.2.2.1 Rheumatoid Arthritis (RA)
5.2.2.2 Ankylosing Spondylitis
5.2.2.3 Systemic Lupus Erythematosus (SLE)
5.3 By End Users
5.3.1 Hospitals
"5.3.2 Research centers
"
5.3.3 Diagnostic laboratories
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Bio-Rad
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Siemens Healthcare
8.3 Abbott Laboratories
8.4 Crescendo Bioscience
8.5 Roche Diagnostics
8.6 SQI Diagnostics
8.7 AESKU Diagnostics
8.8 INOVA Diagnostics
8.9 BioMerieux SA
8.10 Beckman Coulter Inc.
8.11 Hemagen Diagnostics
8.12 Quest Diagnostics
8.13 Eli lilly
8.14 Glaxosmithkline Plc
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
